NCT03668639View on ClinicalTrials.gov

Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 5, 2018

Primary Completion Date

March 1, 2023

Study Completion Date

April 15, 2023

Conditions
Chemotherapy-induced Nausea and VomitingAdverse EventCervical Cancer
Interventions
DRUG

Akynzeo

Weekly administration of akynzeo for five weeks.

DRUG

Dexamethasone

Weekly administration of dexamethasone 12 mg Day 1, 8 mg Day 2-3, and 4 mg Day 4 for five weeks.

Trial Locations (1)

5000

RECRUITING

Department of Oncology, Odense University Hospital, Odense

Sponsors

Collaborators (1)

Helsinn Healthcare SA
All Listed Sponsors
collaborator

Helsinn Healthcare SA

INDUSTRY

lead

Christina Ruhlmann

OTHER

NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin | Biotech Hunter | Biotech Hunter